BETHESDA, Md., Oct. 19 /PRNewswire-USNewswire/ -- In the largest meeting of its kind, nearly 4,000 doctors, scientists, researchers and caregivers will meet in Baltimore, Md., Oct. 21 –23, 2010, to present the latest information and advancements on cystic fibrosis (CF) drug development, research and care.
The conference comes at a critical point in the history of cystic fibrosis, a fatal genetic disease that causes life-threatening lung infections and premature death. For the first time, drugs that treat the underlying cause of the disease have reached the final stages of clinical testing. Up to now, only drugs that treat the symptoms of CF have been available to patients. Therapies in Phase 3 include: ataluren, Bronchitol, denufosol, and VX-770.
Key topics of the conference include:
- Attacking the core defect in CF from every angle;
- The power of patient and family involvement in improving care;
- Grappling with adult issues as people with CF live increasingly longer; and
- Advancements in inhaled antibiotics for CF.
An estimated 30,000 people in the United States have cystic fibrosis, and about 70,000 people worldwide. Ten million Americans are unknowing carriers of a defective CF gene. Fifty years ago, most children with CF died before reaching kindergarten. Today, because of Cystic Fibrosis Foundation-supported drug research and care, people with CF are living into their 30s, 40s and beyond.
The 24th Annual North American Cystic Fibrosis Conference, the largest international gathering of cystic fibrosis research scientists and clinicians.
WHEN & WHERE:
Thursday, Oct. 21 - Saturday, Oct. 23, 2010, at the Baltimore Convention Center, Baltimore, Maryland
- Thurs., Oct. 21 at 4:20 p.m. – "Pipeline: Airway Surface Liquid Modulation," Eric J. Sorscher, M.D., University of Alabama, Birmingham, Alabama
- Friday, Oct. 22, 9:00 a.m. – "What New Models are Teaching Us about CF," David A. Stoltz, M.D., Ph.D., University of Iowa Hospitals, Iowa City, Iowa
- Sat., Oct. 23, 9:00 a.m. – "Transforming CF Healthcare: Partnerships for Life," Donald M. Berwick, M.D., Administrator, Centers for Medicare and Medicaid Services, U.S. Department of Health and Human Services
About the Cystic Fibrosis Foundation
The Cystic Fibrosis Foundation is the world's leader in the search for a cure for cystic fibrosis. The Foundation funds more CF research than any other organization and nearly every CF drug available today was made possible because of Foundation support. Based in Bethesda, Md., the Foundation also supports and accredits a national care center network that has been recognized by the National Institutes of Health as a model of care for a chronic disease. For more information, visit www.cff.org.
Related medicine technology :1
|SOURCE Cystic Fibrosis Foundation|
Copyright©2010 PR Newswire.
All rights reserved
. Georgia Reproductive Specialists Participates in Largest-Ever In Vitro Fertilization Clinical Trial in the World2
. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent3
. International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery4
. Video: The Arizona Heart Institute Announces the Largest Worldwide Experience with Endoluminal Grafting to Treat Thoracic Aortic Aneurysms and Related Pathologies5
. Raydiance Collaborates With Rutgers University and Nations Largest Tissue Bank to Develop Innovative Tissue Processing Approaches6
. Video: New Results From One of the Worlds Largest Breast Cancer Trials Herald Hope for Thousands of Women7
. Universite de Montreal Researchers Simulate Worlds Largest Heart Model Using SGI Technology8
. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study9
. Safety and Efficacy Results Presented From Largest Prospective Controlled Clinical Study of Ulcerative Colitis10
. The Largest Ever Study of Diabetes Shows Intensive Glucose Control Reduces Serious Complications11
. Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD